Business Wire

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu

9.1.2026 11:08:00 CET | Business Wire | Press Release

Share

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets.

Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played an integral role in this transaction and will provide the necessary corporate support, exchange connectivity, collateral management and custodial services.

Strengthening BCP’s Market Position

This acquisition significantly expands BCP’s Bitcoin trading and yield generation capabilities, reinforcing its position as a leading provider of institutional-grade, risk managed Bitcoin yield solutions. By integrating specialized expertise in Bitcoin derivatives and volatility strategies, with a powerful execution and real time risk analytics platform, BCP will capture alternative yield opportunities across both stable and highly volatile market environments.

A Strategic Fit for the Next Phase of Institutional Bitcoin Adoption

The transaction is aligned with BCP’s broader strategy to develop a premier institutional platform for digital asset trading, yield generation and structured solutions. By incorporating these new capabilities, BCP strengthens its ability to deliver:

  • Yield-enhancing derivatives strategies for Bitcoin treasury (including corporate and DAO treasuries), asset-management, and corporate clients, offering an alternative and reliable source of yield on their Bitcoin holdings.
  • Powerful execution infrastructure with embedded market risk solutions designed to support institutional-grade trading of Bitcoin and operational oversight.

PeterPaul Pardi, Managing Partner of Blockstream Capital Partners, said: “Core to the growth of our business is industry-leading talent, proprietary trading strategies and adding to our best-in-class risk management. Deepak brings a rare blend of institutional TradFi rigor and hands-on digital assets trading expertise. By acquiring Numeus’s trading business, we’re adding proven crypto-derivatives and volatility capabilities that institutions increasingly demand, while strengthening our platform offering.”

Deepak Gulati, Co-Chief Investment Officer of Blockstream Capital Management, commented: “The Blockstream Capital Partners team has the ambition, expertise and platform to set the standard for how institutions access and manage their Bitcoin exposure, and I’m thrilled to help accelerate that build.”

Paul Frost-Smith, CEO at Komainu, said: “We’re committed to advancing both innovation and institutional adoption across the Bitcoin ecosystem. BCP is an important partner in that mission, and we’re excited to deepen the relationship as we continue developing and launching new Bitcoin-centric products and services.”

This transaction builds upon BCP’s December 2025 acquisition of Corbiere Capital Management, a Jersey-based equities hedge fund manager led by Rodrigo Rodriguez. Numeus Group is also looking forward to building future value through strategic collaboration with BCP, a leader in the crypto industry.

About BCP Group

Blockstream Capital Partners (BCP) is an investment group of Bitcoin pioneers driving the convergence of Bitcoin and institutional finance. Affiliated with Dr. Adam Back, CEO of Blockstream, the global leader in Bitcoin and blockchain infrastructure, BCP brings together early Bitcoin investors from before the first halving and veteran institutional finance leaders with decades of experience managing global capital.

BCP invests across asset classes - venture capital, private and public equity, credit, real estate, and insurance - and across the entire stack of Bitcoin finance: from infrastructure (including trading, custody, payments, and settlement) to Bitcoin-based applications and financial instruments. Its approach reflects the same philosophy that defines Blockstream: an uncompromising commitment to building the financial infrastructure of the future and a long-term conviction in Bitcoin.

BCP operates a comprehensive investment platform offering institutional-grade Bitcoin solutions designed to deliver Bitcoin-referenced returns and long-term value for investors. With a global presence in key financial hubs, BCP is positioned to serve leading institutional allocators worldwide.

About Numeus Group

Numeus is a digital asset investment firm founded in 2021 by a team of institutional trad-finance and blockchain experts with a team of 33 today across Switzerland, New York, London, and Mauritius. Its asset management division, Forteus, offers absolute-return and directional strategies under an FCA-regulated framework and maintains a strategic partnership with Schroders plc.

About Komainu

Komainu is the institutional gateway for digital assets, headquartered in Jersey, with offices in London, Dubai, and Singapore. Offering bank-grade infrastructure for institutional investors, Komainu provides seamless, connected and secure services with multi-jurisdictional regulatory oversight, merging expertise from traditional financial services with leading security standards for the next generation of institutional digital asset custody, servicing & financing. Komainu (Jersey) Limited is regulated by the Jersey Financial Services Commission. Komainu MEA FZE is regulated by the Dubai Virtual Assets Regulatory Authority.

For more information, visit https://www.komainu.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260109215098/en/

Contacts

Danny Calogero
+44(0)7891 563 294
dcalogero@fullyvested.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye